Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EMEA Grants First Positive Opinion Under Accelerated Assessment To Soliris

This article was originally published in The Pink Sheet Daily

Executive Summary

Alexion’s treatment for a rare blood disease met CHMP’s criteria for accelerated review.

You may also be interested in...



Alexion’s Costly Soliris For AHUS Raises “Cost Of Life” Issues At NICE

NICE is undeniably impressed with Alexion’s Soliris for treating aHUS but wants more data to justify its eye-watering price tag.

Alexion Announces Settlement On Eculizumab Patent; $66.4 Million In Sales For Soliris

The single-product company will pay Oklahoma Medical Research Foundation $10 million, ending a patent-infringement suit.

Alexion Announces Settlement On Eculizumab Patent; $66.4 Million In Sales For Soliris

The single-product company will pay Oklahoma Medical Research Foundation $10 million, ending a patent-infringement suit.

Related Content

Topics

UsernamePublicRestriction

Register

PS065977

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel